Gregg Gilbert
Stock Analyst at Truist Securities
(2.27)
# 2,769
Out of 5,072 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $13.03 | +30.47% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $46.68 | -20.74% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $49.20 | +70.73% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,075.47 | -51.18% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $7.16 | +81.56% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $12.81 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $104.83 | -11.28% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $30.65 | +56.61% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.36 | +1,811.76% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.75 | +19,900.00% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $13.35 | +484.27% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $128.18 | -39.15% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $26.89 | -33.06% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $176.53 | -0.87% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $227.70 | -71.01% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $13.03
Upside: +30.47%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $46.68
Upside: -20.74%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $49.20
Upside: +70.73%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,075.47
Upside: -51.18%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $7.16
Upside: +81.56%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $12.81
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $104.83
Upside: -11.28%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $30.65
Upside: +56.61%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.36
Upside: +1,811.76%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.75
Upside: +19,900.00%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $13.35
Upside: +484.27%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $128.18
Upside: -39.15%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $26.89
Upside: -33.06%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $176.53
Upside: -0.87%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $227.70
Upside: -71.01%